Based on these criteria, we identified seven genes to evaluate in an in vitro functional assay: (1) CTSD, a proteolytic activator [64]; (2) DDIT4, an mTORC1 inhibitor [65]; (3) MT1X, a metallothionein [66]; (4) S100A11, a cell cycle regulator [67, 68]; (5) SERPINE1, a fibrinolysis inhibitor [69]; (6) SNRPA1, an epigenetic modulator in breast cancers [59], and (7) SRGN, a mediator for cellular apoptosis [70]. This evidence concerns the gene S100A11 and breast carcinoma.